Keybank National Association OH Buys New Position in Protagonist Therapeutics, Inc. $PTGX

Keybank National Association OH bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,286 shares of the company’s stock, valued at approximately $452,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Farther Finance Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Protagonist Therapeutics by 1.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after acquiring an additional 193 shares during the period. Maryland State Retirement & Pension System boosted its stake in Protagonist Therapeutics by 2.3% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock worth $751,000 after acquiring an additional 196 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Protagonist Therapeutics by 8.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock worth $258,000 after acquiring an additional 221 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its holdings in Protagonist Therapeutics by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock worth $4,109,000 after purchasing an additional 253 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $137.64 on Friday. The stock has a market cap of $8.85 billion, a price-to-earnings ratio of -76.04 and a beta of 1.79. Protagonist Therapeutics, Inc. has a fifty-two week low of $50.49 and a fifty-two week high of $141.10. The firm’s 50-day simple moving average is $109.46 and its 200 day simple moving average is $97.80.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The firm had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. On average, sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director Bryan Giraudo sold 6,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total transaction of $600,000.00. Following the transaction, the director directly owned 31,825 shares in the company, valued at approximately $3,182,500. This trade represents a 15.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the completion of the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. The trade was a 53.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 162,880 shares of company stock valued at $16,539,792. 5.19% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PTGX shares. Wall Street Zen downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Wolfe Research assumed coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price for the company. Wedbush boosted their target price on Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. TD Cowen reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Finally, Citigroup reiterated an “outperform” rating on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $116.93.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.